Navigation Links
Genomma Lab Internacional Acquires UNIGASTROZOL
Date:7/29/2008

MEXICO CITY, July 29 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma" or "the Company"), a leading Mexican over-the-counter pharmaceuticals and personal care products company announced yesterday that it had acquired the brand and related rights and registrations of UNIGASTROZOL, from Unipharm de Mexico, S.A. de C.V. This over-the-counter product is used for the reduction and control of gastrointestinal symptoms that are produced by excessive acid secretion and is also helpful in the treatment of gastritis, heartburn, reflux and esophagitis. It is based on a molecule that allows for faster absorption than that of Omeoprazol.

With this acquisition, Genomma Lab complements its line of anti-acid products, in particular its product Genoprazol. The category under which Unigastrozol participates reached sales of over US$ 50 million in 2007.

This is Genomma's first acquisition since listing on the Mexican Stock Exchange in June, when it raised capital seeking to accelerate growth.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing over-the-counter pharmaceutical and personal care products companies in Mexico and has a growing international presence. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has significantly grown its revenue and profitability through a combination of a successful new product development process, consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB".

Web Site: http://www.genommalab.com

Contact in Mexico City: Kristi King Etchberger, CFO; kking@genommalab.com; Tel. (55) 5081 0000

Contacts in NY: Maria Barona/Kenia Vargas; mbarona@i-advize.com; Tel. 212 406 3691/3695


'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genomma Lab Prices Initial Public Offering and Begins Trading on Mexican Stock Exchange
2. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. announces Second Quarter 2008 Results Conference Call
3. Cogdell Spencer Inc. Acquires Summit Professional Plaza I and II in Brunswick, Georgia
4. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
5. Food Bank For New York City Acquires FoodChange
6. Concentra Acquires Assets of Renew Health & Wellness
7. DaVita Acquires Majority Stake in HomeChoice Partners, Inc.
8. NNN Healthcare/Office REIT Acquires St. Mary Physicians Center in Long Beach, California
9. NNN Healthcare/Office REIT Acquires 2750 Monroe Boulevard in Valley Forge, Pennsylvania
10. Hologic Acquires Biolucent, Inc.
11. Radiation Therapy Services Acquires North Carolina Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... ... today that nominations will be accepted February 8, 2016 through May 8, ... Awards include the Information Security Executive® of the Year, which recognizes executives ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort with ... time to make a change in public health,” states Carole Baggerly, Director of ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now ... country. The AutismOne 2016 Conference, which is being held May 25-29 at the Loews ... elsewhere about helpful interventions and causes of chronic illness in children. , Very recent ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... has added Kybella® to his medical and surgical expertise. Technically known as deoxycholic ... injectable medication used as a non-surgical alternative for reduction of fat below the ...
(Date:2/6/2016)... Pekin, IL (PRWEB) , ... February 06, 2016 ... ... the recovery phases of eating disorder treatment helps to reduce the frequency and ... “Tasks of the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb.8, 2016 Aesthetic Devices - ... Medical Devices sector report, "Aesthetic Devices - Medical Devices ... currently in pipeline stage. This report ... and primary research by GlobalData,s team of industry experts. ... removed or altered based on the availability and relevance ...
(Date:2/8/2016)... SAN DIEGO , Feb. 8, 2016  Neurocrine ... the Company will report its fourth quarter and year-end ...  February 11, 2016.  Neurocrine will then host a live ... and provide a Company update Thursday afternoon, February 11, ... Time). http://www.neurocrine.com . --> http://www.neurocrine.com ...
(Date:2/8/2016)... N.J. , Feb. 8, 2016   GS1 ... healthcare professionals to guide them through GS1 Standards implementation ... Drug Administration (FDA) Unique Device Identification (UDI) rule. ... GS1 US; Beth Gibson , senior director industry ... , industry development director, GS1 US --> ...
Breaking Medicine Technology: